Fierce Healthcare November 8, 2023
Industry and patient stakeholders who aren’t totally on board with the Biden administration’s Medicare Drug Price Negotiation Program are hoping that to-be-determined updates for the coming years tackle their concerns over access, innovation and pricing head on.
The program outlined by last year’s Inflation Reduction Act allows Medicare to negotiate the prices of 10 Medicare Part D drugs for 2026, with more Part B and Part D products becoming eligible in later years.
Expansions outlined in the law, as well as opportunities for drugmakers to renegotiate, mean that the Centers for Medicare and Medicaid Services (CMS) is already working on new guidances and processes for the years to come, said Meena Seshamani, M.D., deputy administrator and director for the Center...
Today's Sponsors
Today's Sponsor